Dexlansoprazole
Brand names: Dexilant Β· Active ingredient: Dexlansoprazole
In short: Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks. Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief
What is Dexlansoprazole used for?
Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks.
Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age.
Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.
Dexlansoprazole dosage
Table 1: Recommended Dexlansoprazole Delayed-Release Capsules Dosage Regimen by Indication in Patients 12 Years of Age and Older
Indication | Dosage of Dexlansoprazole Capsules | Duration
Healing of EE | One 60 mg capsule once daily. | Up to 8 weeks.
Maintenance of Healed EE and Relief of Heartburn | One 30 mg capsule once daily. | Controlled studies did not extend beyond 6 months in adults and 16 weeks in patients 12 to 17 years of age.
Symptomatic Non-Erosive GERD | One 30 mg capsule once daily. | 4 weeks.
For patients with moderate hepatic impairment (Child-Pugh Class B), the recommended dosage is 30 mg dexlansoprazole delayed-release capsule once daily for up to eight weeks. Dexlansoprazole delayed-release capsule is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) .
Take without regard to food.
Missed doses: If a dose is missed, administer as soon as possible. However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time. Do not take two doses at one time to make up for a missed dose.
Swallow whole; do not chew.
For patients who have trouble swallowing capsules, dexlansoprazole delayed-release capsules can be opened and administered with applesauce as follows:
Place one tablespoonful of applesauce into a clean container.
Open capsule.
Sprinkle intact granules on applesauce.
Swallow applesauce and granules immediately. Do not chew granules. Do not save the applesauce and granules for later use.
Alternatively, the capsule can be administered with water via oral syringe or nasogastric (NG) tube.
Administration with Water in an Oral Syringe
Open the capsule and empty the granules into a clean container with 20 mL of water.
Withdraw the entire mixture into a syringe.
Gently swirl the syringe in order to keep granules from settling.
Administer the mixture immediately into the mouth. Do not save the water and granule mixture for later use.
Refill the syringe with 10 mL of water, swirl gently, and administer.
Refill the syringe again with 10 mL of water, swirl gently, and administer.
Administration with Water via a NG Tube (β₯16 French)
Open the capsule and empty the granules into a clean container with 20 mL of water.
Withdraw the entire mixture into a catheter-tip syringe.
Swirl the catheter-tip syringe gently in order to keep the granules from settling, and immediately inject the mixture through the NG tube into the stomach. Do not save the water and granule mixture for later use.
Refill the catheter-tip syringe with 10 mL of water, swirl gently, and flush the tube.
Refill the catheter-tip syringe again with 10 mL of water, swirl gently, and administer.
How to take Dexlansoprazole β instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Adverse Reactions
Advise patients to report to their healthcare provider if they experience any signs or symptoms consistent with:
Hypersensitivity Reactions
Acute Tubulointerstitial Nephritis
Clostridium difficile-Associated Diarrhea
Bone Fracture
Severe Cutaneous Adverse Reactions
Cutaneous and Systemic Lupus Erythematosus
Cyanocobalamin (Vitamin B12) Deficiency
Hypomagnesemia and Mineral Metabolism
Drug Interactions
Advise patients to report to their healthcare provider if they are taking rilpivirine-containing products or high-dose methotrexate .
Pregnancy
Advise a pregnant woman of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy .
Administration
Take without regard to food.
Missed doses: If a dose is missed, administer as soon as possible. However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time. Do not take two doses at one time to make up for a missed dose.
Swallow whole; do not chew. β¦
Warnings & precautions
Do not take this medicine if: Dexlansoprazole delayed-release capsules are contraindicated in patients with known hypersensitivity to any component of the formulation . Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis and urticaria .
PPIs, including dexlansoprazole delayed-release capsules, are contraindicated with rilpivirine-containing products .
Dexlansoprazole Delayed-Release Capsules, 60 mg contain FD&C Yellow # 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow # 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
In adults, symptomatic response to therapy with dexlansoprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.
Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia). In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Discontinue dexlansoprazole and evaluate patients with suspected acute TIN .
Published observational studies suggest that PPI therapy like dexlansoprazole may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. β¦
Dexlansoprazole side effects
The following serious adverse reactions are described below and elsewhere in labeling:
Acute Tubulointerstitial Nephritis
Clostridium difficile-Associated Diarrhea
Bone Fracture
Severe Cutaneous Adverse Reactions
Cutaneous and Systemic Lupus Erythematosus
Cyanocobalamin (Vitamin B12) Deficiency
Hypomagnesemia and Mineral Metabolism
Fundic Gland Polyps
Risk of Heart Valve Thickening in Pediatric Patients Less than Two Years of Age
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults
The safety of dexlansoprazole was evaluated in 4,548 adult patients in controlled and single-arm clinical trials, including 863 patients treated for at least six months and 203 patients treated for one year. Patients ranged in age from 18 to 90 years (median age 48 years), with 54% female, 85% Caucasian, 8% Black, 4% Asian, and 3% Other races. Six randomized controlled clinical trials were conducted for the treatment of EE, maintenance of healed EE, and symptomatic GERD, which included 896 patients on placebo, 455 patients on dexlansoprazole 30 mg capsules, 2,218 patients on dexlansoprazole 60 mg capsules, and 1,363 patients on lansoprazole 30 mg once daily. β¦
Drug interactions
Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with dexlansoprazole and instructions for preventing or managing them.
Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 3: Clinically Relevant Interactions Affecting Drugs Coadministered with Dexlansoprazole and Interactions with Diagnostics
Antiretrovirals
Clinical Impact: | The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance.
Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with dexlansoprazole may increase toxicity of the antiretroviral drugs.
There are other antiretroviral drugs which do not result in clinically relevant interactions with dexlansoprazole.
Intervention: | Rilpivirine-containing products: Concomitant use with dexlansoprazole is contraindicated . See prescribing information. β¦
About this medicine
The active ingredient in dexlansoprazole delayed-release capsules, a proton pump inhibitor, is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl] methyl} sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its molecular formula is: C16H14F3N3O2S, with a molecular weight of 369.36. Dexlansoprazole has the following chemical structure:
Dexlansoprazole is a white to off white crystalline powder which melts with decomposition at 143Β° to 144Β°C. Dexlansoprazole is practically insoluble in water, freely soluble in dimethylformamide, soluble in methanol, slightly soluble in ethyl acetate and acetonitrile, practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules. β¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d7452a26-db20-42fc-868a-a3e3606ca895. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate